The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

@article{Graff2005ThePK,
  title={The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.},
  author={Jeremy R. Graff and Ann M. McNulty and Kimberly Ross Hanna and Bruce W. Konicek and Rebecca L Lynch and Spring N Bailey and Crystal Banks and Andrew R. Capen and Robin Goode and Jason E Lewis and Lillian Sams and Karen L. Huss and Robert M. Campbell and Philip W. Iversen and Blake Lee Neubauer and Thomas J. Brown and Luna C. Musib and Sandaruwan Geeganage and Donald Thornton},
  journal={Cancer research},
  year={2005},
  volume={65 16},
  pages={7462-9}
}
Activation of protein kinase Cbeta (PKCbeta) has been repeatedly implicated in tumor-induced angiogenesis. The PKCbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses angiogenesis and was advanced for clinical development based upon this antiangiogenic activity. Activation of PKCbeta has now also been implicated in tumor cell proliferation, apoptosis, and tumor invasiveness. Herein, we show that Enzastaurin has a direct effect on human tumor cells, inducing apoptosis and suppressing… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 186 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Phase 1 study of LY317615, a protein kinase Ch inhibitor

  • RS Herbst, DE Thornton, MS Kies
  • Proc of ASCO 2002;21:82a
  • 2002
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…